TrialGedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
Trial details
- Registry ID
- NCT05501886
- Phase
- Phase 3
CELC
Celcuity Inc
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
2Trials in this database
4Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)NCT05501886 | CELC | Phase 3 | Active not recruiting | 2026-06-30Estimated |
| Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)NCT06757634 | CELC | Phase 3 | Recruiting | 2029-03-31Estimated |
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Trial details
- Registry ID
- NCT06757634
- Phase
- Phase 3
Latest recorded trial changes
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
NCT06757634 · Celcuity Inc
Planned enrollment increased by 506 participants
− Before
674 participants (planned)
+ After
1180 participants (planned)
Primary completion date changed
− Before
31 Dec 2027
+ After
31 Mar 2029
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
NCT05501886 · Celcuity Inc
Primary completion date changed
− Before
30 Jun 2025
+ After
30 Jun 2026
Recruitment status changed
− Before
Recruiting
+ After
Active not recruiting